Policy & Regulation
Ali Named CEO at Oak Hill Bio
18 May 2022 - - US-based clinical-stage neonatology and rare disease therapeutics company Oak Hill Bio has appointed Tauhid Ali, Ph.D. as the company's first chief executive officer, the company said.

Ali has more than 25 years of experience in the global biopharmaceutical industry, with broad management and leadership experience in translational research, drug development, and corporate strategy.

He has served as an advisor to Oak Hill Bio since inception. He has public market experience as the chief operating officer and director of JATT Acquisition Corp, a special acquisition company with a focus on the life science sector.

His prior experience also includes serving as executive vice president of Translational and Clinical Science at Cambrian Biopharma, a biotech venture capital holding company.

Prior to that, he spent five years at Takeda (NYSE: TAK), where he served as vice president of Search and Translational Science (Rare Diseases Therapy Area Unit) and also founded and led TAKcelerator, a virtual rare disease biotech unit within Takeda.

Within its first two years, TAKcelerator initiated the development of multiple investigational therapies, including drug candidates to treat acute-on-chronic liver disease, CDKL5 Deficiency Disorder (a genetic developmental and seizure disorder), and Stargardt disease (a rare genetic condition causing blindness).

Dr. Ali has previously worked with UCB Pharma (OTC: UCBJY), Ipsen Group (OTC: APSEY), and Shire Pharmaceuticals.

Oak Hill Bio was established with the licensing of two clinical-stage and four preclinical investigational therapeutics from Takeda.

OHB-607 (formerly TAK-607) is a proprietary, recombinant version of human insulin-like growth factor 1 (IGF-1) designed to help promote continued development and maturation of vital organs, and the vasculature that supports them, in infants born extremely prematurely.

OHB-101 (formerly TAK-752) is being investigated for the treatment of an array of rare autoimmune diseases.

In 2022 Oak Hill intends to advance the ongoing Phase 2b clinical study of OHB-607 for complications of premature birth and initiate Phase 2 trials of OHB-101 in rare autoimmune diseases.

Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical company Ltd.